Care following intravenous thrombolysis (IVT) is critical to ensure safety, monitor for complications, and begin secondary prevention. Recent trials have reshaped traditional practices. Below is an overview of updated standards, supported by modern evidence.
Patients receiving tPA should undergo close monitoring in an ICU or step-down unit for the first 24 hours. This includes:
ENCHANTED Trial: Compared intensive BP lowering (SBP <140 mmHg) to guideline-based target (SBP <180 mmHg) after thrombolysis. Intensive strategy showed no difference in functional outcome.
Clinical Pearl: Target SBP <180 mmHg remains standard post-IVT, though intensive reduction is safe in selected patients.
AVERT Trial: Found that very early, frequent mobilization (<24h post-stroke) may worsen outcomes.
Additional Evidence: Several studies suggest that early mobilization between 12–24 hours post-tPA is generally safe, may shorten hospital stay, but has not been shown to significantly impact long-term functional outcomes.
Guideline Update: Delay mobilization for at least 12–24 hours post-tPA. Initiate rehab once medically stable and neurological status is assessed.
ELAN Trial (2023): Early DOAC initiation (≤48h for minor, 3–6d for moderate) was non-inferior to delayed start, with similar ICH risk.
OPTIMAS Trial (2024): Confirmed that early initiation (≤4 days) of anticoagulation was non-inferior to delayed start (≥7 days) for prevention of recurrent ischemic stroke, with no increase in sICH.
Clinical Pearl: Both trials support earlier DOAC use in AF-related strokes, personalized by stroke severity and hemorrhagic risk.
Despite the success of tPA and endovascular therapy, many patients do not achieve full reperfusion or functional recovery. Investigators have explored adjunctive treatments aimed at improving outcomes when added to standard thrombolysis. These fall into three main categories: antiplatelets, neuroprotectives, and sonothrombolysis (microbubbles).
ARTIS tested IV aspirin 300 mg within 90 minutes of alteplase. The trial was stopped early due to increased symptomatic ICH (4.3% vs. 1.6%) with no functional improvement. Conclusion: Early aspirin post-tPA is not recommended.
TREND enrolled 380 patients with NIHSS 4–20 and noncardioembolic stroke. Tirofiban was given as IV bolus and 72-hour infusion vs. aspirin. Result: Early neurologic deterioration was reduced (4.2% vs 13.2%; RR 0.32; p = .002), with no increase in ICH.
RESCUE BT2 included 948 patients with mild stroke or early neurologic worsening, without thrombolysis. Tirofiban vs. aspirin showed improved excellent outcomes (mRS 0–1: 29.1% vs. 22.2%; RR 1.26; p = .02) and similar sICH rates (1.0% vs. 0%).
Citicoline was tested in several large trials including ICTUS. No functional benefit was demonstrated, and it is not routinely used in acute stroke care.
NXY-059, a free-radical scavenger, showed early promise in SAINT I but failed in SAINT II. Result: No proven benefit, not in clinical use.
Nerinetide was tested in EVT patients. Overall trial was neutral, but in patients not receiving tPA, there was a signal for improved functional outcome. Alteplase appears to degrade nerinetide.
Colchicine (anti-inflammatory) is under investigation for vascular protection post-stroke (e.g., CONVINCE). No current role in acute thrombolysis. CHANCE3 trial showed no benefits of Colchicine for stroke prevention.
CHOICE randomized EVT patients with incomplete reperfusion (eTICI 2b50–2c) to IA alteplase 0.225 mg/kg vs. placebo. Improved mRS 0–1 at 90 days (59% vs 40%; p = .03). No increase in sICH. Suggests benefit of IA alteplase after EVT.
PEARL tested IA alteplase 0.225 mg/kg post-EVT in 324 patients (42% with prior IVT). More excellent outcome (mRS 0–1) was seen with IA alteplase: 44.8% vs. 30.2% (RR 1.45; 95% CI 1.08–1.96); no significant increase in sICH or death.
ANGEL-TNK enrolled 255 patients post successful EVT (eTICI ≥2b50) without prior IV lysis. IA tenecteplase 0.125 mg/kg vs. standard care. Results: better mRS 0–1 with IA TNK (40.5% vs. 26.4% – p = 0.02); no increase in sICH or mortality.
CLOTBUST used continuous TCD ultrasound with IV tPA. Improved recanalization rates were seen, especially in M1 occlusion, but limited by skull penetration and operator dependence.
Experimental studies using ultrasound + microbubbles aim to enhance clot lysis and perfusion. Small human trials suggest feasibility but this remains investigational.
While IV thrombolysis and EVT remain first-line treatments, adjunctive therapies are emerging to improve outcomes. Tirofiban shows some beneficial effect in select patients. Intra-arterial lytics may improve outcomes after thrombectomy. Neuroprotection remains an unmet goal, and sonothrombolysis awaits broader validation.
While intravenous alteplase remains the standard thrombolytic for acute ischemic stroke, several trials now support alternative agents and delivery strategies. This review highlights key studies investigating tenecteplase (TNK), reteplase, and intra-arterial (IA) thrombolysis following thrombectomy.
Tenecteplase is a genetically engineered alteplase variant with higher fibrin specificity and longer half-life, allowing single bolus administration. It has shown promise in multiple RCTs:
The RAISE trial compared IV reteplase (18 mg + 18 mg) to standard alteplase within 4.5 hours of stroke onset:
Clinical Pearl: Reteplase is promising but not yet FDA-approved for stroke.
Several recent trials evaluated IA thrombolytics as adjunct therapy following successful mechanical thrombectomy, targeting residual microthrombi or no-reflow phenomena.
| Trial | Agent / Route | Time Window | mRS 0–1 | Safety |
|---|---|---|---|---|
| EXTEND-IA TNK | TNK IV (0.25 mg/kg) | <4.5 h | Improved vs tPA | No safety concerns |
| RAISE | Reteplase IV (18+18 mg) | <4.5 h | 79.5% vs 70.4% (tPA) | Similar ICH / death |
| CHOICE | IA tPA (0.225 mg/kg) | Post-MT | 59% vs 40% | No ↑ in sICH |
| ANGEL-TNK | IA TNK (0.125 mg/kg) | 4.5–24 h | 40.5% vs 26.4% | Safe |
| PEARL | IA tPA (0.225 mg/kg) | <24 h | 44.8% vs 30.2% | Safe |
With increasing evidence from multiple RCTs, both tenecteplase and reteplase show promise as alternatives to alteplase for acute ischemic stroke. Intra-arterial thrombolytics after thrombectomy also appear to enhance outcomes without added bleeding risk. As protocols evolve, these agents may become more integrated into personalized stroke reperfusion strategies.
Since the original NINDS trial in 1995, the eligibility criteria for intravenous alteplase have progressively widened. Early limitations—such as narrow time windows, strict age cutoffs, and exclusion of patients with unknown onset—have given way to a more nuanced, individualized approach to thrombolytic therapy.
Current guidelines endorse IV alteplase within 4.5 hours of stroke onset for most patients. This expanded window was based on ECASS III, which showed benefit in the 3–4.5h range with acceptable hemorrhagic risk(1).
Patients with unknown time of onset—such as wake-up strokes—are eligible if MRI mismatch (DWI positive, FLAIR negative) confirms likely onset within 4.5 hours. This approach is supported by the WAKE-UP trial(2).
More recent trials have pushed the boundaries further:
Guidelines no longer impose an upper age limit; patients >80 years are eligible if otherwise appropriate. Similarly, patients with preexisting disability (mRS ≥2) can receive alteplase if the stroke is expected to cause new, disabling deficits. Decision-making should incorporate goals of care, functional prognosis, and patient preferences.
Stroke severity is not an exclusion. Very severe (NIHSS >25) or mild-but-disabling strokes can be treated. For non-disabling symptoms (e.g., isolated numbness, mild dysarthria), thrombolysis is not recommended.
The modern approach to IV thrombolysis emphasizes tissue and clinical viability over rigid time rules. Imaging selection with MRI or CT perfusion, patient-centered evaluation of risks and benefits, and growing evidence from trials like TRACE III and CHABLIS-T II continue to expand access to reperfusion therapy.
| Contraindication | Timing / Context | Guideline Statement |
|---|---|---|
| Mild nondisabling stroke | Any Time | IV alteplase is not recommended for NIHSS 0–5 with nondisabling symptoms |
| Extensive hypoattenuation on CT | Any time | Not recommended; indicates irreversible injury |
| Acute intracranial hemorrhage | On CT | Contraindicated |
| Ischemic stroke within prior 3 months | History | Potentially harmful |
| Severe head trauma within 3 months | History | Contraindicated |
| Intracranial or intraspinal surgery | Within 3 months | Potentially harmful |
| History of intracranial hemorrhage | Any time | Potentially harmful |
| Clinical suspicion of subarachnoid hemorrhage | Presentation | Contraindicated |
| GI malignancy | History | Potentially harmful |
| GI bleeding | Within 21 days | Potentially harmful |
| Coagulopathy (platelets <100k, INR >1.7, aPTT >40s) | At baseline | Contraindicated |
| LMWH use – Therapeutic dose | Within 24 hours | Contraindicated |
| Use of direct thrombin or factor Xa inhibitors | Within 48h | Not recommended unless cleared by lab or time |
| Concomitant IV abciximab | Within 90 minutes | Contraindicated |
| Infective endocarditis | Clinical suspicion | Contriandicated |
| Aortic arch dissection | Known or suspected | Contraindicated |
| Intra-axial intracranial tumor | Known | Potentially harmful |
| Condition | Timing / Context | Guideline Summary |
|---|---|---|
| Age >80 | 3–4.5h window | tPA is safe and effective, similar to younger patients |
| Diabetes + prior stroke | 3–4.5h window | tPA may be a reasonable option; similar to 0–3h outcomes |
| Severe stroke (NIHSS >25) | 3–4.5h window | Benefit uncertain; decision individualized |
| Mild but disabling stroke | 3–4.5h window | Reasonable to treat if disabling deficits are present |
| Wake-up or unknown onset | Recognized <4.5h + MRI mismatch | Reasonable to treat if DWI positive, FLAIR negative |
| Preexisting disability | Any time | May be reasonable; consider goals of care and prognosis |
| Early improvement | Any time | Reasonable if residual deficits remain disabling |
| Seizure at onset | Any time | Reasonable if deficit attributed to stroke, not postictal |
| Low or high blood glucose | Initially abnormal | Reasonable to treat if glucose normalized before tPA |
| Warfarin use | INR ≤1.7 | Reasonable to treat |
| Recent lumbar puncture | Within 7 days | May be considered |
| Recent arterial puncture | Non-compressible site, <7 days | Uncertain benefit; case-by-case |
| Recent major trauma | <14 days (non-head) | Reasonable; weigh stroke risk vs. bleeding |
| Recent major surgery | <14 days | May be considered if benefit outweighs risk |
| Menstruation | Ongoing or recent | Reasonable in most cases; inform about increased flow |
| Extracranial cervical dissection | <4.5h | Probably safe and reasonable |
| Unruptured aneurysm (<10mm) | Known | Reasonable to treat |
| Cardiac thrombus / MI history | Recent MI | May be considered; STEMI location influences risk |
| Pregnancy | Any time | Reasonable if benefit outweighs bleeding risk |
| Stroke mimics | Presentation | Reasonable; sICH risk is low |
In the mid-1990s, stroke treatment entered a new era with the approval of intravenous tPA within 3 hours of onset. Over the next three decades, progressive advances in imaging, patient selection, and trial design stretched the therapeutic window far beyond what once seemed possible. Here’s how we got from 3 hours to >24 hours—and what it means for clinical practice today.
The original NINDS trial established that IV alteplase given within 3 hours of stroke onset improved the odds of a favorable outcome (mRS 0–1 at 90 days) by 12% absolute (NNT ≈ 8) despite a 6.4% risk of symptomatic ICH(1).
ECASS III extended the window to 4.5 hours. Patients saw an 8% absolute improvement in functional outcome (mRS 0–1), with ICH risk rising to 7.9%(2). Originally excluded groups (age >80, NIHSS >25, prior stroke + diabetes) are now variably included.
EXTEND used perfusion imaging to identify mismatch up to 9h from onset. Alteplase improved mRS 0–1 rates by ~6% (35.4% vs. 29.5%)(3), with ICH risk ~6%.
Clinical Pearl: CT perfusion or MRI mismatch is now key for late thrombolysis. Widely adopted in comprehensive centers.
WAKE-UP used DWI/FLAIR mismatch on MRI to estimate onset within 4.5h in patients with unknown onset time. It improved outcomes: mRS 0–1 in 53% vs. 42% (NNT ≈ 9)(4), with sICH 2%.
EXPECTS evaluated alteplase in posterior circulation strokes 4.5–24h from onset (NIHSS ≥1, PC-ASPECTS ≥7), excluding planned thrombectomy. Alteplase improved mRS 0–2 (89.6% vs. 72.6%; RR 1.16; P = 0.01) with low sICH (1.7%).
Clinical Pearl: All three trials support tissue-based thrombolysis up to 24h in select LVO patients, especially when perfusion mismatch is present.
HOPE studied tenecteplase 4.5–24h in patients without LVO but with perfusion mismatch. mRS 0–1 at 90 days occurred in 39.7% vs. 29.0% with standard care (adjusted RR 1.37; P=0.047). sICH was low (1.3% vs. 0.7%).
Clinical Pearl: HOPE is the first RCT showing late-window thrombolysis benefits in non-LVO strokes using tenecteplase and perfusion imaging.
Physiologic imaging has extended thrombolysis from a fixed clock-based approach to patient-specific selection—enabling safe and effective treatment well beyond traditional windows.
| Trial | Time Window | LVO | Intervention | Imaging | Outcome | sICH |
|---|---|---|---|---|---|---|
| NINDS | 0–3h | Not specified | IV tPA | NCCT | mRS 0–1: 39% vs 26% | 6.4% |
| ECASS III | 3–4.5h | Not specified | IV tPA | NCCT | mRS 0–1: 52.4% vs 45.2% | 7.9% |
| EXTEND | 4.5–9h | Mixed | IV tPA | CTP or MRI | mRS 0–1: 35.4% vs 29.5% | 6.2% |
| TIMELESS | 4.5–24h | LVO | IV TNK | CTP | Neutral; subgroup benefit | 3.2% |
| CHABLIS-T II | 6–24h | Anterior LVO | IV tPA | CTP | mRS 0–2: 47% vs 20% | Not stated |
For decades, acute ischemic stroke was a therapeutic dead end—an emergency with no effective pharmacologic intervention. That changed in the mid-1990s with the introduction of intravenous tissue plasminogen activator (tPA), a breakthrough that fundamentally reshaped stroke care worldwide.
The idea behind tPA began in the realm of basic science. In the 1970s, scientists studying the body’s natural mechanisms for dissolving blood clots isolated a serine protease from vascular endothelial cells that converted plasminogen to plasmin—an enzyme capable of breaking down fibrin. This molecule, dubbed tissue plasminogen activator (tPA), showed promise as a highly fibrin-specific thrombolytic, meaning it could target clots without widespread degradation of circulating coagulation factors (1). Genentech cloned the human tPA gene in the early 1980s and developed recombinant alteplase, initially targeting myocardial infarction. Its high fibrin selectivity and short half-life made it an attractive candidate for other thrombotic diseases, including stroke.
Desiré Collen, a Belgian scientist, was the first to isolate tissue plasminogen activator (tPA) in the 1970s. This led to recombinant tPA, later developed by Genentech.
The first MI trials using tPA were GISSI-1 and ISIS-2 in the 1980s. The first stroke success came with the landmark NINDS trial in 1995.
The fibrinolytic potential of tPA was first validated in cardiology. In the 1980s, trials like GISSI and ISIS-2 demonstrated that intravenous thrombolytics could restore coronary perfusion and improve survival in acute myocardial infarction. These successes catalyzed interest in applying similar strategies to the cerebral vasculature, despite concerns about bleeding risk and the complexity of stroke pathophysiology (2).
In 1995, the National Institute of Neurological Disorders and Stroke (NINDS) tPA Stroke Study Group published a randomized, double-blind, placebo-controlled trial of alteplase administered within 3 hours of stroke onset. The results were transformative: patients treated with tPA were at least 30% more likely to have minimal or no disability at 3 months compared to placebo (3). Despite a 6.4% rate of symptomatic intracerebral hemorrhage, the trial firmly established the benefit of early reperfusion therapy.
Despite its landmark status, the NINDS trial met considerable skepticism—particularly from emergency physicians who were expected to administer the drug. Critics pointed to the modest absolute benefit (a 12% absolute increase in favorable outcome) alongside a nontrivial risk of symptomatic intracerebral hemorrhage (6.4%) (3). Additionally, the trial’s two-part design, small sample size (~300 patients per group), and reliance on a relatively subjective primary outcome (the NIHSS and modified Rankin at 90 days) raised concerns about reproducibility and generalizability. The fact that imaging and neurologist consultation were required within a narrow 3-hour window seemed impractical in many emergency settings at the time. As a result, many ED physicians hesitated to embrace tPA, viewing it as a high-risk therapy based on a single trial with tightly controlled conditions (6).
The rollout of tPA was not immediate. Concerns about bleeding, narrow time windows, and the need for rapid imaging led to cautious uptake—especially outside the U.S. However, follow-up studies and registry data gradually confirmed its safety and efficacy in real-world settings (4).
By the mid-2000s, tPA was endorsed by major guidelines worldwide, and stroke centers evolved to meet the demands of hyperacute care—ushering in the era of “time is brain.”
The original NINDS trial restricted treatment to within 3 hours, but subsequent studies—like ECASS III—extended the window to 4.5 hours, albeit with stricter inclusion criteria (5). More recently, advanced imaging techniques (e.g., perfusion MRI/CT) have enabled personalized selection of patients beyond traditional time limits, further expanding the reach of thrombolysis.
The approval of tPA for stroke in 1996 marked the first—and for nearly 20 years, only—effective medical therapy for acute ischemic stroke. It sparked the development of dedicated stroke teams, streamlined emergency protocols, and later, paved the way for endovascular thrombectomy. Despite its limitations, tPA remains the cornerstone of acute stroke care and a triumph of translational science.
